The role of inflammatory cytokines in diabetic nephropathy.
暂无分享,去创建一个
[1] M. Cooper,et al. Agents in development for the treatment of diabetic nephropathy , 2008, Expert opinion on emerging drugs.
[2] 小池 伸彦. Induction of reactive oxygen species from isolated rat glomeruli by protein kinase C activation and TNF-α stimulation, and effects of a phosphodiesterase inhibitor , 2008 .
[3] Craig S. Wong,et al. Cytokine gene polymorphism and progression of renal and cardiovascular diseases. , 2007, Kidney international.
[4] Y. Moriwaki,et al. Effect of TNF-α inhibition on urinary albumin excretion in experimental diabetic rats , 2007, Acta Diabetologica.
[5] J. Nadler,et al. Inflammatory mechanisms of diabetic complications , 2007, Current diabetes reports.
[6] G. Ramesh,et al. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. , 2007, Kidney international.
[7] T. Nakagawa. Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. , 2007, American journal of physiology. Renal physiology.
[8] J. Chan,et al. Aberrant activation profile of cytokines and mitogen‐activated protein kinases in type 2 diabetic patients with nephropathy , 2007, Clinical and experimental immunology.
[9] S. Kaneko,et al. Induction of reactive oxygen species from isolated rat glomeruli by protein kinase C activation and TNF-alpha stimulation, and effects of a phosphodiesterase inhibitor. , 2007, Life sciences.
[10] K. Nath,et al. Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia-reperfusion injury. , 2007, Kidney international.
[11] T. Coffman,et al. Toward a mouse model of diabetic nephropathy: is endothelial nitric oxide synthase the missing link? , 2007, Journal of the American Society of Nephrology : JASN.
[12] R. Komers,et al. CYCLO‐OXYGENASE‐2 INHIBITION ATTENUATES THE PROGRESSION OF NEPHROPATHY IN UNINEPHRECTOMIZED DIABETIC RATS , 2007, Clinical and experimental pharmacology & physiology.
[13] Y. Moriwaki,et al. Effect of TNF-alpha inhibition on urinary albumin excretion in experimental diabetic rats. , 2007, Acta diabetologica.
[14] P. Dandona,et al. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade , 2007, Journal of Human Hypertension.
[15] J. Navarro,et al. Renal Pro-Inflammatory Cytokine Gene Expression in Diabetic Nephropathy: Effect of Angiotensin-Converting Enzyme Inhibition and Pentoxifylline Administration , 2007, American Journal of Nephrology.
[16] J. Navarro,et al. Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[17] J. Navarro,et al. Inflammation and diabetic nephropathy , 2006, Current diabetes reports.
[18] S. Kadayıfçılar,et al. Elevated intravitreal interleukin-6 levels in patients with proliferative diabetic retinopathy. , 2006, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.
[19] S. Sizmaz,et al. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy , 2006, Eye.
[20] Jaipaul Singh,et al. Inflammatory Process in Type 2 Diabetes , 2006 .
[21] Felix Eichinger,et al. Modular Activation of Nuclear Factor-κB Transcriptional Programs in Human Diabetic Nephropathy , 2006, Diabetes.
[22] A. Goldfine,et al. Inflammation and insulin resistance. , 2006, The Journal of clinical investigation.
[23] M. Rodríguez-Moran,et al. Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double-blind, placebo-controlled randomized trial. , 2006, Clinical nephrology.
[24] Y. Aso,et al. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. , 2006, The Journal of clinical endocrinology and metabolism.
[25] D. Levine. Hyperfiltration, nitric oxide, and diabetic nephropathy , 2006, Current hypertension reports.
[26] D. Cha,et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. , 2006, Journal of the American Society of Nephrology : JASN.
[27] M. Hollegaard,et al. Cytokine gene polymorphism in human disease: on-line databases, Supplement 3 , 2006, Genes and Immunity.
[28] T. Pantsulaia. Role of TGF-beta in pathogenesis of diabetic nephropathy. , 2006, Georgian medical news.
[29] S. Rich. Genetics of diabetes and its complications. , 2006, Journal of the American Society of Nephrology : JASN.
[30] Jaipaul Singh,et al. Inflammatory process in type 2 diabetes: The role of cytokines. , 2006, Annals of the New York Academy of Sciences.
[31] R. Atkins,et al. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. , 2006, Kidney international.
[32] K. Ley,et al. Leukocyte recruitment and vascular injury in diabetic nephropathy. , 2006, Journal of the American Society of Nephrology : JASN.
[33] W. Jeffcoate,et al. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes , 2005, The Lancet.
[34] C. Flores,et al. Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. , 2005, Kidney international. Supplement.
[35] H. Makino,et al. Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. , 2005, Diabetes care.
[36] J. Navarro,et al. Role of inflammation in diabetic complications. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[37] N. Perico,et al. Emerging drugs for diabetic nephropathy , 2005, Expert opinion on emerging drugs.
[38] T. Lee,et al. Genetics of diabetic nephropathy in type 2 DM: candidate gene analysis for the pathogenic role of inflammation , 2005, Nephrology.
[39] F. Jamali,et al. Protective Effects of Angiotensin II Interruption: Evidence for Antiinflammatory Actions , 2005, Pharmacotherapy.
[40] M. Rodríguez-Moran,et al. Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients--a randomized, equivalent trial. , 2005, Clinical nephrology.
[41] J. Navarro,et al. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. , 2005, Journal of the American Society of Nephrology : JASN.
[42] K. Tuttle. Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease. , 2005, Journal of the American Society of Nephrology : JASN.
[43] R. Atkins,et al. Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. , 2005, Journal of the American Society of Nephrology : JASN.
[44] Mark E. Williams,et al. The next generation of diabetic nephropathy therapies: an update. , 2005, Advances in chronic kidney disease.
[45] A. Krolewski,et al. Evidence for different susceptibility genes for proteinuria and ESRD in type 2 diabetes. , 2005, Advances in chronic kidney disease.
[46] M. Mussap,et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. , 2005, Journal of the American Society of Nephrology : JASN.
[47] L. Gesualdo,et al. Pathogenetic mechanisms of diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.
[48] M. Cooper,et al. Agents in development for the treatment of diabetic nephropathy , 2005, Expert opinion on investigational drugs.
[49] W. Chu,et al. Molecular screening and association analyses of the interleukin 6 receptor gene variants with type 2 diabetes, diabetic nephropathy, and insulin sensitivity. , 2005, The Journal of clinical endocrinology and metabolism.
[50] M. Amini,et al. Comparison of the Effect of Pentoxifylline and Captopril on Proteinuria in Patients with Type 2 Diabetes mellitus , 2005, Nephron Clinical Practice.
[51] A. Cox,et al. Interleukin-1 receptor antagonist allele (ILIRN*2) associated with nephropathy in diabetes mellitus , 1996, Human Genetics.
[52] J. Egido,et al. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[53] H. Grønbaek,et al. The involvement of growth hormone (GH), insulin-like growth factors (IGFs) and vascular endothelial growth factor (VEGF) in diabetic kidney disease. , 2004, Current pharmaceutical design.
[54] Young Seol Kim,et al. Polymorphisms in Interleukin-1β and Interleukin-1 Receptor Antagonist Genes Are Associated with Kidney Failure in Korean Patients with Type 2 Diabetes mellitus , 2004, American Journal of Nephrology.
[55] I. Macdougall,et al. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. , 2004, Journal of the American Society of Nephrology : JASN.
[56] D. Yach,et al. The global burden of chronic diseases: overcoming impediments to prevention and control. , 2004, JAMA.
[57] Yung-Ming Chen,et al. Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[58] C. Langefeld,et al. Heritability of GFR and albuminuria in Caucasians with type 2 diabetes mellitus. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[59] F. Gesek,et al. Pentoxifylline Ameliorates Renal Tumor Necrosis Factor Expression, Sodium Retention, and Renal Hypertrophy in Diabetic Rats , 2004, American Journal of Nephrology.
[60] Lin Xu,et al. Inhibition of Tumor Necrosis Factor-α-Converting Enzyme by a Selective Antagonist Protects Brain from Focal Ischemic Injury in Rats , 2004 .
[61] M. Crook. Type 2 diabetes mellitus: a disease of the innate immune system? An update , 2004, Diabetic medicine : a journal of the British Diabetic Association.
[62] J. Pickup. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. , 2004, Diabetes care.
[63] K. Yudoh,et al. Interleukin-18 enhances monocyte tumor necrosis factor alpha and interleukin-1beta production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis. , 2004, Arthritis and rheumatism.
[64] R. Larkins,et al. Increased hyaluronan production in the glomeruli from diabetic rats: a link between glucose-induced prostaglandin production and reduced sulphated proteoglycan , 1995, Diabetologia.
[65] A. Aljada,et al. Inflammation: the link between insulin resistance, obesity and diabetes. , 2004, Trends in immunology.
[66] R. Atkins,et al. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. , 2004, Kidney international.
[67] G. Feuerstein,et al. Inhibition of tumor necrosis factor-alpha-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats. , 2004, Molecular pharmacology.
[68] R. Hohlfeld,et al. Diagnostic criteria for polymyositis and dermatomyositis , 2003, The Lancet.
[69] C. Bogardus,et al. Variants in the interleukin 6 receptor gene are associated with obesity in Pima Indians. , 2003, Molecular genetics and metabolism.
[70] M. Netea,et al. Selective regulation of intercellular adhesion molecule‐1 expression by interleukin‐18 and interleukin‐12 on human monocytes , 2003, Immunology.
[71] H. Siragy,et al. Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. , 2003, Kidney international.
[72] H. Makino,et al. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. , 2003, Diabetes.
[73] R. Lisak,et al. Role of Neuropoietic Cytokines in Development and Progression of Diabetic Polyneuropathy: From Glucose Metabolism to Neurodegeneration , 2003, Experimental diabesity research.
[74] D. Yach,et al. Globalisation and the prevention and control of non-communicable disease: the neglected chronic diseases of adults , 2003, The Lancet.
[75] M. Bennett,et al. Tumor Necrosis Factor-&agr; Promotes Macrophage-Induced Vascular Smooth Muscle Cell Apoptosis by Direct and Autocrine Mechanisms , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[76] O. Hamdy,et al. Adipokines, inflammation, and the endothelium in diabetes , 2003, Current diabetes reports.
[77] J. Navarro,et al. Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[78] J. Navarro,et al. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[79] J. Cardier,et al. Differential effect of IL-18 on endothelial cell apoptosis mediated by TNF-α and Fas (CD95) , 2003 .
[80] Masafumi Koga,et al. Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. , 2003, Metabolism: clinical and experimental.
[81] Z. Bloomgarden,et al. Inflammation and insulin resistance. , 2003, Diabetes care.
[82] L. Chessa,et al. Six novel ATM mutations in Italian patients with classical ataxia‐telangiectasia , 2003, Human mutation.
[83] Jun Yeun Kim,et al. Identification of novel SNPs in the interleukin 6 receptor gene (IL6R) , 2003, Human mutation.
[84] Joachim Spranger,et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. , 2003, Diabetes.
[85] M. Yılmaz,et al. Combination of Pentoxifylline with Angiotensin Converting Enzyme Inhibitors Produces an Additional Reduction in Microalbuminuria in Hypertensive Type 2 Diabetic Patients , 2003, Renal failure.
[86] J. Vilček. CHAPTER 1 – The cytokines: an overview , 2003 .
[87] R. Zatz,et al. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. , 2003, Kidney international.
[88] F. Gesek,et al. Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. , 2003, American journal of physiology. Renal physiology.
[89] T. Yoshikawa,et al. Interleukin‐6 polymorphism (–634C/G) in the promotor region and the progression of diabetic nephropathy in Type 2 diabetes , 2002, Diabetic medicine : a journal of the British Diabetic Association.
[90] C. Edelstein,et al. Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. , 2002, The Journal of clinical investigation.
[91] Connie J. Wang,et al. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. , 2002, Kidney international.
[92] K. Resch,et al. IFNγ induces functional chemokine receptor expression in human mesangial cells , 2002 .
[93] K. Resch,et al. IFNgamma induces functional chemokine receptor expression in human mesangial cells. , 2002, Clinical and experimental immunology.
[94] T. Hostetter. Prevention of end-stage renal disease due to type 2 diabetes. , 2001, The New England journal of medicine.
[95] S. Coppack. Pro-inflammatory cytokines and adipose tissue , 2001, Proceedings of the Nutrition Society.
[96] J. Manson,et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.
[97] M. Lucia,et al. Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. , 2001, The Journal of clinical investigation.
[98] A. Phillips,et al. Regulation of renal proximal tubular epithelial cell hyaluronan generation: implications for diabetic nephropathy. , 2001, Kidney international.
[99] R. Blantz,et al. Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. , 2001, The Journal of clinical investigation.
[100] H. Zinger,et al. Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFα monoclonal antibody and by pentoxiphylline , 2001, Lupus.
[101] H. Makino,et al. Role of macrophages in the pathogenesis of diabetic nephropathy. , 2001, Contributions to nephrology.
[102] C. Park,et al. High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-ϰB-dependent , 2000, Diabetologia.
[103] D. Heudes,et al. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. , 2000, Diabetes.
[104] G. Pacini,et al. Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. , 2000, Diabetes.
[105] F. Locatelli,et al. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[106] G. Fantuzzi,et al. IL-12–induced IFN-γ is dependent on caspase-1 processing of the IL-18 precursor , 1999 .
[107] M. Puliti,et al. Role of Tumor Necrosis Factor Alpha, Interleukin-1β, and Interleukin-6 in a Mouse Model of Group B Streptococcal Arthritis , 1999, Infection and Immunity.
[108] F. Pociot,et al. Cytokine gene polymorphism in human disease: on-line databases , 1999, Genes and Immunity.
[109] H. Makino,et al. Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-α and inducible nitric oxide synthase in diabetic rat glomeruli , 1999, Diabetologia.
[110] Gerardo Heiss,et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study , 1999, The Lancet.
[111] S. Rich,et al. Is diabetic nephropathy inherited? Studies of glomerular structure in type 1 diabetic sibling pairs. , 1999, Diabetes.
[112] M. Macía,et al. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[113] G. Fantuzzi,et al. IL-12-induced IFN-gamma is dependent on caspase-1 processing of the IL-18 precursor. , 1999, The Journal of clinical investigation.
[114] D. Middleton,et al. An interluekin 1B allele, which correlates with a high secretor phenotype, is associated with diabetic nephropathy. , 1998, Cytokine.
[115] D. Breuillé,et al. Cytokine modulation by PX differently affects specific acute phase proteins during sepsis in rats. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.
[116] M. A. Crook,et al. Is Type II diabetes mellitus a disease of the innate immune system? , 1998, Diabetologia.
[117] A. Ridley,et al. Regulation of TNF‐α‐induced reorganization of the actin cytoskeleton and cell‐cell junctions by Rho, Rac, and Cdc42 in human endothelial cells , 1998, Journal of cellular physiology.
[118] V. Savin,et al. TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. , 1998, Journal of the American Society of Nephrology : JASN.
[119] Ihm Cg. Monocyte chemotactic peptide-1 in diabetic nephropathy. , 1997 .
[120] M. Elder. The Role of Cytokines , 1997 .
[121] C. Ihm. Monocyte chemotactic peptide-1 in diabetic nephropathy. , 1997, Kidney international. Supplement.
[122] H. Okamura,et al. Cloning of a new cytokine that induces IFN-γ production by T cells , 1995, Nature.
[123] M. Endoh,et al. In Situ Hybridization of Interleukin 6 in Diabetic Nephropathy , 1995, Diabetes.
[124] M. Rodríguez-Moran,et al. Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. , 1995, Clinical nephrology.
[125] A. At. Presentación del Instituto «Reina Sofía» de Investigación Nefrológica , 1995 .
[126] A. Ortiz,et al. Involvement of tumor necrosis factor-alpha in the pathogenesis of experimental and human glomerulonephritis. , 1995, Advances in nephrology from the Necker Hospital.
[127] H. Brady. Leukocyte adhesion molecules and kidney diseases. , 1994, Kidney international.
[128] A. Thomson. The cytokine handbook , 1994 .
[129] Y. Tomino,et al. Detection of serum IL-6 in patients with diabetic nephropathy. , 1994, Nephron.
[130] Y. Tomino,et al. mRNA Expression of Growth Factors in Glomeruli From Diabetic Rats , 1993, Diabetes.
[131] E. Wardle. Cytokines: an overview. , 1993, The European journal of medicine.
[132] C. Ruef,et al. Interleukin-6: an autocrine regulator of mesangial cell growth. , 1992, Kidney international.
[133] M. Kondo,et al. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. , 1991, Kidney international.
[134] J. Norton,et al. Pentoxifylline suppression of tumor necrosis factor gene transcription. , 1991, Surgery.
[135] L. Glimcher,et al. Stimulated kidney tubular epithelial cells express membrane associated and secreted TNF alpha. , 1991, Kidney international.
[136] J. Lacy,et al. Interleukin 6 is an autocrine growth factor for mesangial cells. , 1990, Kidney international.
[137] Jiahuai Han,et al. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway , 1990, The Journal of experimental medicine.
[138] H. Mühl,et al. Interleukin 1 and tumor necrosis factor potentiate angiotensin II- and calcium ionophore-stimulated prostaglandin E2 synthesis in rat renal mesangial cells. , 1990, Biochemical and biophysical research communications.
[139] D. Kohan,et al. Regulation of renal transport processes and hemodynamics by macrophages and lymphocytes. , 1990, The American journal of physiology.
[140] G. Habermehl,et al. Interleukin 1-α and tumor necrosis factor-α induce oxygen radical production in mesangial cells , 1990 .
[141] G. Habermehl,et al. Interleukin 1-alpha and tumor necrosis factor-alpha induce oxygen radical production in mesangial cells. , 1990, Kidney international.
[142] S. Akira,et al. Biological and clinical aspects of interleukin 6. , 1990, Immunology today.
[143] F. Balkwill,et al. The cytokine network. , 1989, Immunology today.
[144] E. Seaquist,et al. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. , 1989, The New England journal of medicine.
[145] J. Pfeilschifter,et al. Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat renal mesangial cells. , 1989, Biochemical and biophysical research communications.
[146] N. Perico,et al. Tumor necrosis factor induces glomerular damage in the rabbit. , 1989, The American journal of pathology.
[147] S. Matalon,et al. Tumor necrosis factor and interleukin ICU increase vascular endothelial permeability , 1989 .
[148] R. Ardaillou,et al. Tumor necrosis factor stimulates prostaglandin production and cyclic AMP levels in rat cultured mesangial cells , 1988, FEBS letters.
[149] L. Gooding,et al. Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. , 1988, Journal of immunology.